Podcasts about onc

Episode Summary Particle Health CEO Jason Prestinario joins MedCity Pivot to assess the state of U.S. healthcare interoperability with clear-eyed candor. He grades the technical infrastructure a B — data can move — but gives access governance a C, because the rules around who uses data, and how, remain murky and poorly enforced. Jason draws a direct line between true interoperability and the viability of value-based care: without frictionless data access, accountability for patient outcomes is impossible. The conversation also covers Particle's antitrust lawsuit against Epic, now past its first major legal hurdle, and the broader wave of litigation challenging Epic's market dominance. Jason urges nuance: there's a meaningful difference between patients authorizing their own data use and bad actors harvesting records without consent — and conflating the two risks setting back the entire data-sharing ecosystem. Key Takeaways The data infrastructure gets a B — but access governance is still a C. The technical pipes for moving health records exist, but who can use them, when, and for what purpose remains the critical unsolved problem. Interoperability is a 'nice to have' in fee-for-service care — but it's a hard requirement for value-based care. When a provider is accountable for outcomes that happen outside their four walls, they need data from outside those walls. Information blocking penalties need teeth. Until healthcare organizations believe violations will result in real consequences, the rules won't change behavior — just like speed limits only work when drivers believe tickets are real. There's a critical distinction between patients authorizing their own data use and third parties accessing data without consent. The current Epic lawsuit debate conflates two very different scenarios that deserve separate legal and regulatory treatment. True patient data ownership is still largely a myth. Despite portals and progress, patients still face significant barriers — forgotten logins, provider-controlled systems — to accessing their own medical records programmatically. Links and Resources Connect with Arundhati Parmar aparmar@medcitynews.com Arundhati Parmar (@aparmarbb) on X MedCity News Keywords healthcare interoperability, Particle Health, Jason Prestinario, Epic lawsuit, antitrust healthcare, value-based care, CMS interoperability, TEFCA, Carequality, health data access, information blocking, 21st Century Cures Act, patient data ownership, HIPAA compliance, health information exchange, payer interoperability, digital health data, EHR data sharing, CommonWell, ONC rules Episode Highlights [00:04:22 - 00:05:16] Jason grades the interoperability 'pipes' a B-plus but gives data access governance a C at best. [00:10:56 - 00:12:37] Interoperability shifts from 'nice to have' in fee-for-service to a hard requirement in value-based care. [00:17:05 - 00:19:27] Jason explains why Particle sued Epic and what the case means for the broader healthcare data ecosystem. [00:25:11 - 00:27:11] A key distinction: patient-authorized data use versus unauthorized third-party data harvesting. [00:28:34 - 00:32:44] Why patients still can't easily access their own records — and what it would take to change that. [00:29:02 - 00:29:41] Information blocking penalties only work when organizations believe the consequences are real.

Esta mañana en #Noticias7AM entrevistamos al Dr. Homero Fuentes de la Peña, Médico Oncólogo, además de Presidente y Socio Fundador de ProOncavi AC. Tema: Presentó su libro “Entre balones y barricas”#Uniradioinforma

On this episode of The Dish on Health IT, Tony Schueth is joined by Dr. Thomas Keane, National Coordinator for Health IT at ONC, along with Alix Goss and Janice Reese. The conversation moves between policy, standards, and real-world implementation, with Tony often grounding the discussion in the practical friction points the industry continues to face. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Inspired by stories of the nurses who cared for her cousin, who traveled to the US from the Bahamas for open-heart surgery,  Marguerite Rowell, MSN, MSM/HM, MBA, ONC, SCRN, NEA-BC, decided in the eighth grade that she wanted to be a nurse. She came to the United States, joined Baptist Health South Florida, and spent nearly 25 years advancing from staff nurse to charge nurse, to manager, to director, to Assistant Vice President of Nursing, where she helped open the Miami Cancer Institute and served as interim Chief Nursing Officer. But throughout every promotion, one problem never left her: healthcare finance. Nurse leaders are handed multi-million-dollar budgets and a binder from a training session, and then immediately sent back to the floor, where the commitment to patients and staff takes center stage.  So, she built NurseMath: a mobile app that puts the financial calculations nurse leaders need, ROI, contribution margin, proforma, staffing ratios, right in their pocket, wherever they are. Marguerite makes the case that nurses are multi-dimensional creators at the helm of the innovations that will transform healthcare.    For more information on the podcast bundles, visit ANA's Innovation Website at: https://www.nursingworld.org/practice-policy/innovation/education. Have questions or feedback for the SEE YOU NOW team? Future episode ideas? Contact us at: hello@seeyounowpodcast.com.

In this episode of The Dish on Health IT, Tony Schueth is joined by Dr. Thomas Keane, National Coordinator for Health IT at ONC, along with Alix Goss and Janice Reese. The conversation moves between policy, standards, and real-world implementation, with Tony often grounding the discussion in the practical friction points the industry continues to face. Tony opens by noting that “ONC is ONC again,” setting a lighter tone while also framing the broader conversation around where federal health IT policy is headed. He highlights Dr. Keane's unusual background spanning engineering, clinical practice, and federal leadership, asking how that path shaped his perspective on impact. Dr. Keane explains that his transition into policy was driven by exposure and opportunity, but importantly, he continues to practice medicine. Tony picks up on that point, noting how rare it is for a National Coordinator to still be actively practicing, reinforcing the value of having a policy leader grounded in real-world care delivery. Interoperability at the “Speed of Trust” Tony then shifts the conversation to one of his core themes: interoperability as infrastructure. He references Dr. Keane's framing of interoperability needing to operate at the “speed of trust,” and pushes on the tension between that vision and the reality of legacy systems still dominating the market. Dr. Keane responds by walking through ONC's dual-track approach. On one hand, rulemaking like HTI-5 is pushing toward a FHIR-based, API-driven future. On the other, ONC recognizes that legacy standards are deeply embedded and must continue to be supported. He also points to the CMS Health Tech Ecosystem initiative as a powerful example of how government can accelerate progress by convening stakeholders rather than relying solely on regulation. Tony brings Janice Reese into the discussion to ground this vision in implementation reality. Janice emphasizes that the biggest barriers are not the APIs themselves, but the underlying trust infrastructure. She outlines identity, security, consent, and directory services as the key gaps preventing interoperability from scaling nationally. Imaging as a Case Study in Misaligned Incentives Tony pivots to diagnostic imaging, framing it as a clear example where standards exist but adoption lags. He references the continued reliance on physical media like CDs and asks whether the issue is less about technology and more about incentives and certification. Dr. Keane agrees and shares a detailed example from his time as a radiologist, describing how consolidating imaging workflows improved efficiency and reduced turnaround times. He uses this to illustrate the broader point: the technology exists, but economic and operational incentives often work against seamless data exchange. He also notes that ONC's recent RFI is intended to better understand these barriers and inform future rulemaking. Tony keeps the tone light with a quick aside about McDonald's and queue efficiency, but uses it to reinforce a serious point. Even when better systems exist, organizations sometimes stick with less efficient models because they are familiar or expected. Prior Authorization: Progress, but Still Fragmented Tony then moves into prior authorization, referencing CMS-0057 and Da Vinci use cases as signs of progress, particularly on the medical side. He contrasts that with the ongoing fragmentation in pharmacy prior authorization and asks how ONC is thinking about bridging that gap. Dr. Keane emphasizes that standards alone are not enough. Real progress depends on making those standards usable in practice. He points to ongoing work with EHR vendors, PBMs, and intermediaries to ensure that real-time prescription benefit tools deliver complete and accurate information that clinicians can trust. Tony and Alix build on this by connecting real-time benefit checks to broader price transparency efforts, suggesting that combining these capabilities could fundamentally change how patients and providers make decisions together at the point of care.  Price Transparency: Still Not Patient-Friendly Tony directly challenges the current state of price transparency, asking how the industry moves beyond “check-the-box” compliance to delivering something that is actually usable for patients. Dr. Keane acknowledges that while progress has been made, much of the data remains too complex and not sufficiently tailored to individual patients. He notes that CMS continues to iterate on requirements, but that making cost information actionable at the point of care remains an ongoing challenge. AI: From Hype to Real Utility Tony transitions to AI with a callback to a joke Dr. Keane made about AI either transforming healthcare or reducing it to three bullet points. He uses that setup to ask whether AI can realistically make complex healthcare data usable for patients and clinicians. Dr. Keane answers with a firm yes, pointing to existing use cases in radiology and clinical workflows where AI is already improving accuracy and efficiency. He shares examples of AI identifying stroke patterns, highlighting abnormalities in imaging, and even summarizing clinical reports. Tony then brings the conversation back to risk, asking about overreliance on AI and how policy should address bias and accountability. Dr. Keane is clear that responsibility still sits with the clinician, noting that physicians are trained to recognize bias and must independently validate AI-driven insights. Janice and Alix add that AI's success ultimately depends on the quality and standardization of the underlying data. Without consistent, trusted data, AI will simply amplify existing gaps. Information Blocking and Enforcement Tony closes the main discussion by turning to information blocking, asking what message ONC has for organizations that continue to restrict data access under the guise of technical or legal constraints. Dr. Keane outlines a range of enforcement mechanisms, from corrective action plans to potential financial penalties. He emphasizes that while ONC prefers to work with organizations to resolve issues, the expectation is clear: data must flow. Final Call to Action: Data Liquidity As always, Tony ends with a call-to-action question. If there were one thing the industry could do starting tomorrow, what would it be? Dr. Keane's answer is direct: make data liquid. He ties this back to reducing administrative burden, improving price transparency, and enabling better patient decision-making. The goal is a system where data flows seamlessly, at the direction of the patient, to support care and operations. Janice and Alix close by reinforcing that the industry does not lack standards or policy direction. The real challenge is aligning stakeholders and scaling adoption.  

LA PICADITA DE LOS SÁBADOS con María Esther Álvarez 25-04-2026 Entrevistas a: Horacio Pascuariello (Periodista Responsable de la Sección de Pesca Deportiva del "Diario Crónica") Juan Pablo Peralta @JuamPaPeralta (Periodista acreditado en Casa Rosada) Alfredo Belasio (Abogado Tributarista, Escritor) Gabriel Biondi (Creador de contenido tech en Instagram y TikTok) Julio Lautersztain (Médico Oncólogo) Mirta Carranza (Fundadora y Directora del Instituto I.S.A.R.A.) Aldo Boscareo y Sandra Sánchez (Dulce Sazon, Comodoro Rivadavia)

Julio Lautersztain (Médico Oncólogo) La Picadita de los Sábados @picaditasbado

In this session, Pat Iyer, a seasoned blogger and past president of the American Association of Legal Nurse Consultant, shares her journey of blogging since 2009 and reveals insider techniques to gain visibility among attorneys seeking specialized expertise. Joined by co-moderator Barbara Levin, herself a distinguished legal nurse consultant and educator, they explore how regular, targeted content transforms a static presence into a dynamic magnet for new opportunities. Throughout the episode, listeners will learn why traditional, unchanging websites are no longer enough and how consistent blogging becomes a critical tool for connecting with overstretched attorneys. Pat explains how blog content not only attracts search engines but also builds credibility, authority, and lasting professional relationships. Real-world examples illustrate how a single blog post can directly lead to client inquiries, highlighting the blog's role as an ever-present, quietly persuasive marketing force. Along with actionable blogging advice, Pat and Barbara touch on upcoming legal nurse consultant events, content repurposing hacks, and the importance of leveraging AI and other technologies to maximize reach. The episode is packed with tips for overcoming common blogging pitfalls, ensuring consistency, and turning knowledge into real business growth. What You'll Learn in This Episode on Blogging Strategies for Legal Nurse Consultants: How to Stand Out in a Crowded Field  Here are 5 discussion questions answered in the podcast: Why is it becoming more challenging for legal nurse consultants to stand out and get noticed by attorneys in a crowded market? How does consistent blogging set legal nurse consultants apart from competitors and boost their visibility with attorneys? What are the most effective types of blog topics that resonate with attorneys and potentially lead to new cases? How can blogs be repurposed for other marketing activities such as newsletters, LinkedIn posts, and videos? What are common mistakes legal nurse consultants make when blogging, and how can they ensure their blogs actually attract and engage the right audience? Listen to our podcasts or watch them using our app, Expert.edu, available at legalnursebusiness.com/expertedu. Get the free transcripts and also learn about other ways to subscribe. Go to Legal Nurse Podcasts subscribe options by using this short link: http://LNC.tips/subscribepodcast. Grow Your LNC Business 13th LNC SUCCESS® ONLINE CONFERENCE April 23, 24, and 25, 2026 Skills, Strategy, Results Gain deposition mastery, marketing confidence, and clinical–legal insight from industry leaders you can apply to your next case and client call. Build a Practice Attorneys Remember Learn exactly how to showcase expertise, attract referrals, and turn complex medical records into clear, defensible stories that win trust. Learn From the Best—Then Ask Them Anything Get step-by-step training, live “hot seat” solutions, and exclusive VIP Q&A time with Pat Iyer to accelerate your LNC growth. Register now- Limited spots available Your Presenter for Blogging Strategies for Legal Nurse Consultants: How to Stand Out in a Crowded Field Pat Iyer Pat Iyer is a seasoned legal nurse consultant and business coach, renowned for her expertise in guiding new legal nurse consultants to successfully break into the field. As the host of the Legal Nurse Podcast, Pat addresses critical challenges that legal nurse consultants face, such as difficulty in landing clients and a lack of response from attorneys. Through her insightful episodes, she emphasizes the importance of effectively communicating one's value to potential clients. With a wealth of experience, Pat has empowered countless consultants to overcome these hurdles and thrive in their careers. Connect with Pat Iyer by email at patiyer@legalnusebusiness.com Barbara Levin Barbara Levin, BSN, RN, ONC, LNCC, CMSRN, FNAON, is a nationally recognized expert witness and legal nurse consultant with more than two decades of experience. Known for her precision, clarity, and ability to mentor others, Barbara has co-hosted ten LNC Success® Conferences alongside Pat and brings a wealth of practical knowledge to help LNCs thrive. Connect with Barbara Levin by email at Barbara@barbarajlevin.com

In this episode of Surfacing Secrets, Balad'EAU transports you to the last wild frontier on the planet: Antarctica. As the "White Sentinel" for our future climate, this frozen region holds critical data, but it doesn't give up its secrets without a fight.Hosted by Lyne Morissette, this episode takes you inside a high-stakes Ocean Networks Canada (ONC) mission to install a subsea observatory in one of the most hostile environments on Earth. To get there, the team had to survive the 20-meter waves of the Drake Passage, dodge wandering icebergs, and navigate the logistical puzzle of working 2,000 kilometers away from civilization.You'll hear from three key figures at the heart of this expedition:Dr. Juanjo Dañobeitia, a 40-year veteran of the ice and Director of the European Multidisciplinary Seafloor and water column Observatory (EMSO).Ruchie Custan, an ONC engineer dubbed the "Antarctic Sherpa" after a grueling mountain ascent.Bradley Wells, the engineer who built the two-ton steel armor designed to keep the science alive.From "MacGyvering" equipment in sub-zero gales to the rare sense of solidarity found at the Spanish Juan Carlos I station, this is a raw look at what it actually takes to keep the data flowing in a place that is actively trying to freeze your equipment—and you—to a halt.Learn more & explore further:Ocean Networks Canada: https://www.oceannetworks.caONC Data & Real-time Observatories (Ocean 3.0): https://data.oceannetworks.caInstitut de Ciències del Mar (CSIC): https://www.icm.csic.es/en CTV News Feature on the ONC Expedition: https://youtu.be/s4AGeJkSvVAThe Juan Carlos I base: https://youtu.be/zUPOkVaagWk?si=skSwO-gCH08Hz4vI Listen to the full interview with Andrew Lewin on the How to Protect The Ocean Podcast:https://www.speakupforblue.comEpisode produced by: Balad'EAU with the generous support of Ocean Networks Canada.Ocean Networks Canada is one of Canada's Major Research Facilities and an initiative of the University of Victoria. It is primarily funded by the Canada Foundation for Innovation and Fisheries and Oceans Canada.Editing and production: Tommy Goupil

Five Good Things with Janae Sharp and Megan Antonelli: A rapid-fire segment highlighting positive developments in digital health. Janae and Megan share insights on recent innovations, successful implementations, and emerging trends that are driving progress in healthcare technology. Learn about cutting-edge solutions improving patient outcomes Discover how technology is enhancing healthcare accessibility Gain insight into successful digital health implementations Stay informed about positive industry trends shaping the future of care Janae Sharp, Founder, The Sharp Index Megan Antonelli, Founder & CEO, HealthIMPACT

The Legal Nurse Podcast, hosted by Pat Iyer, explores ways to sharpen skills for Legal Nurse Consultants (LNCs) in this special episode. Pat is joined by her colleague Barbara Levin to discuss the upcoming 13th LNC Success Conference, a live virtual event built for both beginners and experienced LNCs. The conversation shows how online learning for legal nurses has changed, starting from the need to stay connected during the pandemic, and points out the specific chances this conference gives for learning and meeting others. Listeners get a look at the sessions, including ways to attract attorney clients, using AI for business growth, clinical tips from medical and legal experts, and the reality of how money-driven healthcare decisions work. The episode looks at how the conference combines clinical, legal, and business viewpoints, making it a key event for anyone wanting to grow their legal nurse consulting work. Pat Iyer and Barbara Levin highlight the ease and worth of the virtual setup, the hands-on skills and networking it offers, and the lively community it builds. Whether you are starting out in LNC, looking for expert knowledge, or wanting to make professional connections, this episode gives a preview of the learning and growth waiting at the LNC Success Conference. What You'll Learn in This Episode on Empowering Legal Nurses: Conference Highlights on Marketing, AI, Litigation, and Clinical Expertise Here are 5 discussion questions answered in the podcast: How did the pandemic start a new period of virtual conferences for Legal Nurse Consultants? What different viewpoints do attorneys, physicians, and seasoned LNCs bring to the event? How are marketing and AI changing the LNC business? How do virtual conferences help LNCs move past obstacles in professional growth and networking? What real-world skills and private tips are shared that attendees almost never hear anywhere else? Listen to our podcasts or watch them using our app, Expert.edu, available at legalnursebusiness.com/expertedu. Get the free transcripts and also learn about other ways to subscribe. Go to Legal Nurse Podcasts subscribe options by using this short link: http://LNC.tips/subscribepodcast. Grow Your LNC Business 13th LNC SUCCESS® ONLINE CONFERENCE April 23, 24, and 25, 2026 Skills, Strategy, Results Gain deposition mastery, marketing confidence, and clinical–legal insight from industry leaders you can apply to your next case and client call. Build a Practice Attorneys Remember Learn exactly how to showcase expertise, attract referrals, and turn complex medical records into clear, defensible stories that win trust. Learn From the Best—Then Ask Them Anything Get step-by-step training, live “hot seat” solutions, and exclusive VIP Q&A time with Pat Iyer to accelerate your LNC growth. Register now- Limited spots available https://youtu.be/P3_jvUq9gwY Your Presenter for Empowering Legal Nurses: Conference Highlights on Marketing, AI, Litigation, and Clinical Expertise Pat Iyer Pat Iyer is a seasoned legal nurse consultant and business coach, renowned for her expertise in guiding new legal nurse consultants to successfully break into the field. As the host of the Legal Nurse Podcast, Pat addresses critical challenges that legal nurse consultants face, such as difficulty in landing clients and a lack of response from attorneys. Through her insightful episodes, she emphasizes the importance of effectively communicating one's value to potential clients. With a wealth of experience, Pat has empowered countless consultants to overcome these hurdles and thrive in their careers. Connect with Pat Iyer by email at patiyer@legalnusebusiness.com Barbara Levin Barbara Levin, BSN, RN, ONC, LNCC, CMSRN, FNAON, is a nationally recognized expert witness and legal nurse consultant with more than two decades of experience. Known for her precision, clarity, and ability to mentor others, Barbara has co-hosted ten LNC Success® Conferences alongside Pat and brings a wealth of practical knowledge to help LNCs thrive. Connect with Barbara Levin by email at Barbara@barbarajlevin.com

The Department of Health and Human Services is reshuffling its top officials for data, artificial intelligence, and technology back under its chief information officer, undoing a 2024 reorganization of those roles under the Biden administration. In a Tuesday announcement, HHS said the department's chief AI officer, chief technology officer, and chief data officer would move from the Office of the Assistant Secretary for Technology Policy/Office of the National Coordinator for Health IT, known as ASTP/ONC, back to the Office of the Chief Information Officer. The department is also ending the dual title of ASTP/ONC and reverting it back to just ONC. According to the press release, the reversal is aimed at reinforcing “OCIO's statutory responsibility for enterprise IT, cybersecurity, and data operations.” The move, the department said, also enables ONC to focus on its mission of health IT policy standards and certification. HHS CIO and acting CAIO Clark Minor said in a statement included in the release that the move allows the department to “move faster on shared platforms, protect our systems more effectively, and support ONC and the operating divisions with the technology capabilities they need to innovate for patients.” The Biden-era reorganization was first announced in July 2024 and generally moved functions away from the OCIO, with a goal of clarifying and consolidating those responsibilities. The Federal Communications Commission has tapped the Food and Drug Administration's former chief digital officer as its new IT chief, the independent agency announced Monday. Farhan Khan, who left the FDA for a private-sector role in August 2025, takes over as the FCC's chief information officer following the retirement of Allen Hill last October. Deputy CIO Don Tweedie had been serving in the role in an acting capacity since then. At the FDA, Khan oversaw digital transformation projects for the agency, managing a $200 million budget and team of more than 400 staffers, according to the FCC's press release. Khan began his federal career as a team lead with the Department of Justice in 2009, per his LinkedIn profile. He later served as the Department of Transportation's director of infrastructure, the FDA's CTO, the Federal Deposit Insurance Corp.'s IT infrastructure operations chief, and the U.S. Army's director of architecture and integration for the senior executive service. As the FCC's CIO, Khan — who holds a master's degree from George Washington in information systems — will be charged with overseeing the agency's overarching technical priorities, leading modernization efforts and securing data. The Daily Scoop Podcast is available every Monday-Friday afternoon. If you want to hear more of the latest from Washington, subscribe to The Daily Scoop Podcast  on Apple Podcasts, Soundcloud, Spotify and YouTube.

Welcome to "Never Wonder Where Your Next Case Is Coming From," a special power series hosted by Pat Iyer and Barbara Levin. In this episode, Pat Iyer, a nationally recognized legal nurse consultant and past president of the American Association of Legal Nurse Consultants, teams up with Barbara Levin, a clinical scholar at Massachusetts General and a renowned expert in medical-legal arenas. Together, they dive deep into the art of strategic networking for legal nurse consultants (LNCs), offering practical, actionable strategies for building lasting, profitable relationships with attorneys. Throughout the episode, you'll hear Pat Iyer and Barbara Levin break down the steps to successful networking, from identifying the right people and places to connect, to mastering your elevator pitch, to leveraging digital platforms like LinkedIn. They tackle common challenges legal nurses face, like standing out in a crowded field and staying visible to decision makers, while sharing their own real-world experiences and lessons learned. This session is packed with insights not just for newcomers but for experienced LNCs who want to revitalize their case flow and business development strategies. Whether you're curious about choosing the most effective events, framing your value to attorneys, or navigating the evolving landscape of online visibility, this episode is designed to inspire you to take confident, targeted action. Pat Iyer and Barbara Levin also introduce upcoming opportunities to refine your skills, including their interactive LNC Success Conference, where you can get live coaching, hands-on feedback, and network with peers and industry leaders. Don't miss their expert guidance on making sure you'll never have to wonder where your next case is coming from! What You'll Learn in This Episode on The Secrets of Effective Networking for Legal Nurse Consultants Here are 5 discussion questions answered in the podcast: Pat Iyer and Barbara Levin discuss the difference between visibility and positioning at conferences. Why do you think simply being “visible” isn't enough for legal nurse consultants (LNCs)? According to Barbara Levin, what strategic questions should LNCs ask themselves before registering for an event, and how can their answers shape their networking outcomes? Pat Iyer mentioned that attorneys often don't fully understand what LNCs do. How can LNCs more effectively communicate their value to attorneys in networking situations? The episode differentiates between attending nurse-focused versus attorney-focused events. What are some of the unique advantages of each, and how might attending both benefit your LNC business? Christopher DiBella raised concerns about the use of AI in generating legal and medical documents. What risks and benefits did he identify, and how does he suggest balancing technology with human oversight? Listen to our podcasts or watch them using our app, Expert.edu, available at legalnursebusiness.com/expertedu. Get the free transcripts and also learn about other ways to subscribe. Go to Legal Nurse Podcasts subscribe options by using this short link: http://LNC.tips/subscribepodcast. Grow Your LNC Business 13th LNC SUCCESS® ONLINE CONFERENCE April 23, 24, and 25, 2026 Skills, Strategy, Results Gain deposition mastery, marketing confidence, and clinical–legal insight from industry leaders you can apply to your next case and client call. Build a Practice Attorneys Remember Learn exactly how to showcase expertise, attract referrals, and turn complex medical records into clear, defensible stories that win trust. Learn From the Best—Then Ask Them Anything Get step-by-step training, live “hot seat” solutions, and exclusive VIP Q&A time with Pat Iyer to accelerate your LNC growth. Register now- Limited spots available Your Presenter for The Secrets of Effective Networking for Legal Nurse Consultants Pat Iyer Pat Iyer is a seasoned legal nurse consultant and business coach, renowned for her expertise in guiding new legal nurse consultants to successfully break into the field. As the host of the Legal Nurse Podcast, Pat addresses critical challenges that legal nurse consultants face, such as difficulty in landing clients and a lack of response from attorneys. Through her insightful episodes, she emphasizes the importance of effectively communicating one's value to potential clients. With a wealth of experience, Pat has empowered countless consultants to overcome these hurdles and thrive in their careers. Connect with Pat Iyer by email at patiyer@legalnusebusiness.com Barbara Levin Barbara Levin, BSN, RN, ONC, LNCC, CMSRN, FNAON, is a nationally recognized expert witness and legal nurse consultant with more than two decades of experience. Known for her precision, clarity, and ability to mentor others, Barbara has co-hosted ten LNC Success® Conferences alongside Pat and brings a wealth of practical knowledge to help LNCs thrive. Connect with Barbara Levin by email at Barbara@barbarajlevin.com

In Episode 128 of DC EKG, Joe Grogan is joined by Kat McDavitt and Lisa Bari, co-hosts of the Health Tech Talk Show, for a practical conversation on what the next wave of health IT policy could unlock for patients and innovation. They break down the proposed HTI 5 rule from ONC, why it is framed as deregulation, and how it aims to shift the market away from long EHR certification checklists toward one core goal: data that moves. The conversation digs into information blocking, TEFCA, patient access, and the reality of who controls health data in practice. Joe presses a simple question: if it is “my data,” why do patients still struggle to pull a complete record? Kat and Lisa explain how HIPAA is often used as a barrier instead of a bridge, how secondary data use markets operate, and why privacy gets complicated in a world of apps, brokers, and advanced compute. They also explore how HTI 5 connects to the AI wave, why state AI laws can create risk for innovation, and whether ideas like a Medicare app library help patients or end up picking winners too late. In This Conversation What HTI 5 is and why ONC is scaling back parts of EHR certification Information blocking, TEFCA, and what real interoperability requires Patient access vs business-to-business exchange and why complete records are still hard to get HIPAA and the gap between intent and real-world data sharing Screen scraping, automation, and why data access is becoming an AI issue State AI regulation and federal direction on AI policy ,Timestamps0:36 Intro1:14 Welcome Kat McDavitt and Lisa Bari2:05 Lisa on her new role and what she is working on4:17 First reactions to HTI 5 and EHR deregulation7:34 HTI 5 in plain English11:27 Who controls health data and why this rule matters14:08 Why patients still cannot easily access complete records17:36 HIPAA and how it is used today22:24 Privacy outside HIPAA and secondary use25:50 How HTI 5 targets information blocking28:16 Screen scraping and why it is controversial36:09 How HTI 5 connects to healthcare AI47:28 Medicare app library concerns52:05 Closing and where to find Health Tech Talk Show Health Tech Talk Show YouTube channel: https://www.youtube.com/@HealthTechTalkShow/streams SEO Keywords (Megaphone)HTI 5, ONC, information blocking, TEFCA, interoperability, healthcare APIs, HIPAA, health data access, healthcare AI policy, data liquidity, screen scraping, Medicare app library About Our GuestsKat McDavitt is co-host of the Health Tech Talk Show, President and Founding Partner of Innsena, and CEO and Founder of the Zorya Foundation.Lisa Bari is the Vice President of Policy and Partnerships at Innovaccer, where she leads health and AI policy, government relations, and global partnerships. She is the creator and host of the Policy Stack podcast, co-host of the Health Tech Talk Show, and a board member of the Zorya Foundation. Previously, she was the founding CEO of Civitas Networks for Health.Podcast: DC EKG with Joe GroganEpisode: 128Guests: Kat McDavitt and Lisa BariSponsor: Survivors for Solutions – https://survivorsforsolutions.orgExecutive Producer: John “CZ” Czwartacki, DC EKG PodcastProducer: Julie Riga, Stay on Course Studios – https://www.stayoncourse.studio

In Episode 128 of DC EKG, Joe Grogan is joined by Kat McDavitt and Lisa Bari, co-hosts of the Health Tech Talk Show, for a practical conversation on what the next wave of health IT policy could unlock for patients and innovation. They break down the proposed HTI 5 rule from ONC, why it is framed as deregulation, and how it aims to shift the market away from long EHR certification checklists toward one core goal: data that moves. The conversation digs into information blocking, TEFCA, patient access, and the reality of who controls health data in practice. Joe presses a simple question: if it is “my data,” why do patients still struggle to pull a complete record? Kat and Lisa explain how HIPAA is often used as a barrier instead of a bridge, how secondary data use markets operate, and why privacy gets complicated in a world of apps, brokers, and advanced compute. They also explore how HTI 5 connects to the AI wave, why state AI laws can create risk for innovation, and whether ideas like a Medicare app library help patients or end up picking winners too late. In This Conversation What HTI 5 is and why ONC is scaling back parts of EHR certification Information blocking, TEFCA, and what real interoperability requires Patient access vs business-to-business exchange and why complete records are still hard to get HIPAA and the gap between intent and real-world data sharing Screen scraping, automation, and why data access is becoming an AI issue State AI regulation and federal direction on AI policy ,Timestamps0:36 Intro1:14 Welcome Kat McDavitt and Lisa Bari2:05 Lisa on her new role and what she is working on4:17 First reactions to HTI 5 and EHR deregulation7:34 HTI 5 in plain English11:27 Who controls health data and why this rule matters14:08 Why patients still cannot easily access complete records17:36 HIPAA and how it is used today22:24 Privacy outside HIPAA and secondary use25:50 How HTI 5 targets information blocking28:16 Screen scraping and why it is controversial36:09 How HTI 5 connects to healthcare AI47:28 Medicare app library concerns52:05 Closing and where to find Health Tech Talk Show Health Tech Talk Show YouTube channel: https://www.youtube.com/@HealthTechTalkShow/streams SEO Keywords (Megaphone)HTI 5, ONC, information blocking, TEFCA, interoperability, healthcare APIs, HIPAA, health data access, healthcare AI policy, data liquidity, screen scraping, Medicare app library About Our GuestsKat McDavitt is co-host of the Health Tech Talk Show, President and Founding Partner of Innsena, and CEO and Founder of the Zorya Foundation.Lisa Bari is the Vice President of Policy and Partnerships at Innovaccer, where she leads health and AI policy, government relations, and global partnerships. She is the creator and host of the Policy Stack podcast, co-host of the Health Tech Talk Show, and a board member of the Zorya Foundation. Previously, she was the founding CEO of Civitas Networks for Health.Podcast: DC EKG with Joe GroganEpisode: 128Guests: Kat McDavitt and Lisa BariSponsor: Survivors for Solutions – https://survivorsforsolutions.orgExecutive Producer: John “CZ” Czwartacki, DC EKG PodcastProducer: Julie Riga, Stay on Course Studios – https://www.stayoncourse.studio

In this episode of the podcast we are explore the way the UK Armed Services has been radically upping its game in terms of the support, promotion and development of professional engineering careers. To do this, I'm joined today by Squadron Leader David Littlemore from the Royal Air Force, currently executive officer infrastructure at Cyber and Specialist Operations Command. David is also fellow of the Institution of Civil Engineers, in fact, the only chartered civil engineer in the RAF, and I'd say that he is also a passionate advocate for merging the best of military and civilian engineering training to create complete and capable professional engineers fit for the future. David's engineering career journey was unorthodox. He started straight from school, aged 16, working in a bridge design office, where he progressed through ONC and then HNC studies before gaining a degree in Civil Engineering at Durham University. He then switched to the military by being commissioning into the Royal Air Force in 2008. Since then his career has bridged the gap between civilian consultancy and high-stakes military infrastructure, tackling work across the UK and from the South Atlantic to the Middle East.And today, as a Chartered Civil Engineer, he is certainly testament to the "long winding road" of modern professional engineering careers. Beyond his technical expertise in project management and infrastructure delivery, he mentors young technicians and engineers and is committed to helping the next generation understand the profound value of professional recognition, and what it takes to build a career.ResourcesRAF Cyber and Specialist Operations CommandRAF professional engineering careersDavid Littlemore Linked InICE routes to membershipICE CouncilQUEST scholarships

Esta mañana en #Noticias7AM entrevistamos al Dr. Homero Fuentes De La Peña, Médico Oncólogo, Presidente y Socio Fundador de Pro Oncavi A.C. (Pro Oncología y Calidad deVida). Tema: La reciente conmemoración del Día Mundial del Cáncer, el pasado 04 de febrero#Uniradioinforma

In this episode of Surfacing Secrets, Balad'EAU explores what scientific discovery actually looks like — not as a single "aha" moment, but as a long-term process built on curiosity, observation, and a willingness to pay attention when things get weird. Hosted by Lyne Morissette, Scientific Discoveries takes you inside Ocean Networks Canada (ONC) to uncover how discoveries emerge when scientists stop chasing answers — and start watching continuously. From marine heatwaves and unexpected ecosystem insights to solar storms interfering with ocean instruments, this episode reveals how long-term data turns surprises into understanding. You'll hear from three voices at the heart of ONC's story: Richard Dewey, former Science Director at ONC, oceanographer Kohen Bauer, who works at the intersection of ocean data, tools, and models at ONC Gwyn Lintern, an early ONC collaborator now with Natural Resources Canada (NRCan), whose work bridges science, risk, and real-world decision-making Together, they share how ONC evolved from answering scientific questions to generating vast, open datasets that researchers — and government departments — now rely on to understand ocean processes, ecosystem health, and environmental risk. This episode dives into: How continuous observation transforms raw data into scientific discovery Why looking for the weird is often the starting point of real breakthroughs What marine heatwaves like the Blob revealed about changing ocean conditions How solar flares were detected deep in the ocean — without anyone looking for them Why understanding when ecosystems are functioning well matters in an age of eco-anxiety How ONC's data supports science, policy, and public safety You'll also hear sounds captured directly from the ocean — including underwater acoustics recorded by ONC's observatories — reminding us that sometimes, discovery isn't something you see, but something you hear. Listen closely — the ocean is always telling a story. Learn more & explore further Ocean Networks Canada: https://www.oceannetworks.ca ONC data & real-time observatories (Ocean 3.0): https://data.oceannetworks.ca ONC YouTube channel (including underwater sounds and observatory footage): https://www.youtube.com/@OceanNetworksCanada Richard Dewey's YouTube channel (sailing the Salish sea): https://www.youtube.com/@o0Splunge0o/videos  Listen to the full interview with Andrew Lewin on the How to Protect The Ocean Podcast: https://www.speakupforblue.com/show/speak-up-for-the-ocean-blue/podcast-55/ Episode produced by: Balad'EAU With the generous support of: Ocean Networks Canada Ocean Networks Canada is one of Canada's Major Research Facilities and an initiative of the University of Victoria. It is primarily funded by the Canada Foundation for Innovation and Fisheries and Oceans Canada. Editing and producation: Tommy Goupil

DC EKG with Joe Grogan: A Healthcare Policy Podcast Ep. 122 In this episode of DC EKG with Joe Grogan: A Healthcare Policy Podcast, Joe recaps the first Healthcare AI Policy Summit, held on December 10th in Washington, DC, with his co-host for the event, Naomi Lopez, founder of Nexus Policy Consulting. They walk through the big themes shaping healthcare AI right now: how HHS is approaching AI adoption, what real regulatory clarity could look like, and how new federal initiatives like ACCESS and TEMPO may reshape chronic disease management for Medicare patients. Joe and Naomi unpack HHS Deputy Secretary Jim O'Neill's view of AI in government, from using large models to improve physician productivity, payment integrity, and care coordination to managing privacy and re-identification risk when working with federal health data. They dig into the ACCESS Medicare payment model and the FDA TEMPO initiative, explaining how these pilots test AI and machine learning tools in real-world chronic disease management (hypertension, diabetes, musculoskeletal pain, and depression), and what that means for Medicare payment models, FDA oversight, and healthcare innovation. The conversation then widens to physician burnout, interoperability, rural care, and the role of states and federal preemption in setting the rules for healthcare AI. If you care about the real-world impact of healthcare AI on policy, payment, and patients, this episode offers a clear, practical summary of what the summit revealed and what to watch next. Today Joe and Naomi cover: Jim O'Neill's vision for AI at HHS, including internal AI adoption and keeping a direct line open for small innovators. ACCESS and TEMPO as new federal test beds for AI in chronic disease management and Medicare payment. How wearables, remote monitoring, and “virtual ICU” models can support aging in place and reduce pressure on state budgets. Ways AI can reduce documentation burden, support care coordination, and act as a first-line triage tool without replacing clinicians. The emerging idea of personal AI agents that help patients navigate the system and share the right data with clinicians. How AI-enabled diagnostics and tools can expand access in rural and underserved communities. Why interoperability, ONC's API rules, and the balance between state AI regulation and federal preemption will shape how quickly these tools scale. The potential for tech companies to become Medicare Part B providers under ACCESS, and what that means for reimbursement and competition. Key Takeaways: Healthcare AI is being built into policy through programs like ACCESS and TEMPO, tying AI tools to Medicare payment and FDA pathways in chronic disease management. Regulatory clarity and predictable routes from FDA clearance to Medicare reimbursement are essential for sustained AI adoption. AI is currently most valuable as a force multiplier for physician productivity, taking on administrative and analytic work so clinicians can focus on patients. Personal AI agents may become a primary interface between patients and the health system, coordinating data, benefits, and care. Rural and underserved communities could benefit significantly if payment and regulatory rules support AI-enabled diagnostics and remote care. Interoperability, state AI laws, and federal preemption will determine whether healthcare AI stays in pilots or reaches patients nationwide. Joe's guest, Naomi Lopez, is the founder of Nexus Policy Consulting and a leading voice in healthcare policy, healthcare AI, and state health reform. She co-founded a healthcare AI working group with Joe Grogan and co-hosted the inaugural Healthcare AI Policy Summit on December 10th in Washington, DC.

Podcast TitleDC EKG with Joe Grogan: A Healthcare Policy Podcast Ep. 122 Healthcare AI Gets Real: Naomi Lopez on ACCESS, TEMPO, and the Future of Care Episode Description-In this episode of DC EKG with Joe Grogan: A Healthcare Policy Podcast, Joe recaps the first Healthcare AI Policy Summit, held on December 10th in Washington, DC, with his co-host for the event, Naomi Lopez, founder of Nexus Policy Consulting. They walk through the big themes shaping healthcare AI right now: how HHS is approaching AI adoption, what real regulatory clarity could look like, and how new federal initiatives like ACCESS and TEMPO may reshape chronic disease management for Medicare patients. Joe and Naomi unpack HHS Deputy Secretary Jim O'Neill's view of AI in government, from using large models to improve physician productivity, payment integrity, and care coordination to managing privacy and re-identification risk when working with federal health data. They dig into the ACCESS Medicare payment model and the FDA TEMPO initiative, explaining how these pilots test AI and machine learning tools in real-world chronic disease management (hypertension, diabetes, musculoskeletal pain, and depression), and what that means for Medicare payment models, FDA oversight, and healthcare innovation. The conversation then widens to physician burnout, interoperability, rural care, and the role of states and federal preemption in setting the rules for healthcare AI. If you care about the real-world impact of healthcare AI on policy, payment, and patients, this episode offers a clear, practical summary of what the summit revealed and what to watch next. Today Joe and Naomi cover: Jim O'Neill's vision for AI at HHS, including internal AI adoption and keeping a direct line open for small innovators. ACCESS and TEMPO as new federal test beds for AI in chronic disease management and Medicare payment. How wearables, remote monitoring, and “virtual ICU” models can support aging in place and reduce pressure on state budgets. Ways AI can reduce documentation burden, support care coordination, and act as a first-line triage tool without replacing clinicians. The emerging idea of personal AI agents that help patients navigate the system and share the right data with clinicians. How AI-enabled diagnostics and tools can expand access in rural and underserved communities. Why interoperability, ONC's API rules, and the balance between state AI regulation and federal preemption will shape how quickly these tools scale. The potential for tech companies to become Medicare Part B providers under ACCESS, and what that means for reimbursement and competition. Key Takeaways: Healthcare AI is being built into policy through programs like ACCESS and TEMPO, tying AI tools to Medicare payment and FDA pathways in chronic disease management. Regulatory clarity and predictable routes from FDA clearance to Medicare reimbursement are essential for sustained AI adoption. AI is currently most valuable as a force multiplier for physician productivity, taking on administrative and analytic work so clinicians can focus on patients. Personal AI agents may become a primary interface between patients and the health system, coordinating data, benefits, and care. Rural and underserved communities could benefit significantly if payment and regulatory rules support AI-enabled diagnostics and remote care. Interoperability, state AI laws, and federal preemption will determine whether healthcare AI stays in pilots or reaches patients nationwide. Naomi Lopez is the founder of Nexus Policy Consulting and a leading voice in healthcare policy, healthcare AI, and state health reform. She co-founded a healthcare AI working group with Joe Grogan and co-hosted the inaugural Healthcare AI Policy Summit on December 10th in Washington, DC.

OpenAI's Sam Altman says individuals should use GPT-5 to help them with their healthcare journey. Dr. Doug Fridsma, former ONC chief science officer and current CMIO at Health Universe, says there are things to consider when using the tech.

La Dra. Isabel Matilde Chinchía, Hematóloga y Oncóloga Clínica del Grupo de Linfomas de la ACHO en Colombia, en conjunto con el Dr. José Sandoval, Hematólogo Oncólogo del MOFFITT Cancer Center en Estados Unidos, compartieron las actualidades en linfoma no Hodgkin (LNH) B difuso de células grandes.Su intervención se llevó a cabo durante el 9° Congreso Nacional de Actualización en Hematología y Oncología de la ACHO, realizado del 14 al 16 de noviembre de 2025 en Cartagena de Indias, Colombia.Fecha de grabación: 15 de noviembre de 2025 Referencia:Este contenido se basa en la interpretación crítica de la evidencia científica disponible, así como en la experiencia clínica del o los ponentes como profesionales de la salud en instituciones de referencia.Para profundizar en los conceptos discutidos, se recomienda al profesional de la salud consultar literatura científica vigente, guías clínicas internacionales y la normatividad aplicable en su país.Material exclusivo para profesionales de la salud. Este material ha sido desarrollado únicamente con fines educativos e informativos y no tiene la intención de sustituir el juicio clínico de los profesionales de la salud. Las opiniones y declaraciones presentadas en este contenido son responsabilidad exclusiva de los ponentes y no reflejan necesariamente la postura institucional de ScienceLink ni de terceros mencionados. La información presentada se basa en el conocimiento y la experiencia profesional de los ponentes. La veracidad, exactitud y actualidad científica de los datos son de su exclusiva responsabilidad. Así mismo garantizan que el contenido utilizado no infringe derechos de autor de terceros y asumen toda responsabilidad por su uso. Se deberán de revisar las indicaciones aprobadas en el país con estricto apego al marco regulatorio aplicable para cada uno de los tratamientos y medicamentos comentados.

Esta mañana en #Noticias7AM entrevistamos a Dr. Homero Fuentes De La Peña, Médico Oncólogo, Presidente y Socio Fundador de Pro Oncavi A.C. (Pro Oncología y Calidad de Vida).  Tema: Noviembre, mes azul sobre salud masculina y mes dedicado a la concientización y lucha contra el cáncer depróstata.  #Uniradioinforma

In this episode of Metabolic Matters, I'm joined by Jen Nolan, BS, MS, ONC, TAP and Dr. Kirsten West, ND, LAc, FABNO — two brilliant practitioners trained under me in the Metabolic Approach to Cancer. Together, we explore what healing looks like when built on collaboration, community, and love. Jen, owner of Remission Nutrition and graduate of our Terrain Advocate Program, blends oncology nutrition with whole-person care. Dr. West, a Fellow of the American Board of Naturopathic Oncology and part of the Riordan Clinic team, bridges conventional and naturopathic medicine, offering patients compassionate, comprehensive guidance.Connect with Our Guests: Jen Nolan Website: https://www.remissionnutrition.com/explore IG: https://www.instagram.com/remissionnutrition/?hl=enFB: https://www.facebook.com/remissionnutritionDr. Kirsten WestRiordan Clinic: https://riordanclinic.org/staff/kirsten-west-nd-lac-fabno/ About Your HostI'm Dr. Nasha Winters, a global healthcare authority, best-selling author, and educator in the emerging field of integrative oncology and terrain-based cancer care. I host Metabolic Matters to explore the intersections between metabolism, medicine, and meaning.Subscribe, Share & ReviewIf you loved this conversation, please subscribe, rate, and share with a friend or clinician who needs to hear it.Support & Resources:Support Patient Grants: www.mtih.orgBook: The Metabolic Approach to CancerEducation Programs: www.metabolicregen.comSupplements: mitovida.comFollow on SocialsDr. Nasha on InstagramMetabolic Matters InstagramFacebookLinkedInTikTokYouTube Hosted on Acast. See acast.com/privacy for more information.

In this episode of HIPcast, Darlene Falcone, shares her experience as an AI Regulation Specialist and highlights the ONC's HTI-4 Rule. We learn about the complexities of AI regulation at the state level and federal level and why HI professionals need to step up to lead. #HIPcast with Shannan and Seth.HIPcast brought to you by Enterprise Social Record

Professor Dame Carol Robinson is a scientist who was the first female professor of Chemistry at both Cambridge and Oxford Universities. She has been awarded scientific prizes from all over the world for her pioneering work studying complex macromolecules using an instrument called the mass spectrometer.Carol was drawn to science as a child growing up in Folkstone where she started collecting flowers and shells before moving on to breeding mice because she was fascinated by their genetic makeup. She grew to love chemistry in particular and pored over the periodic table in her bedroom.She left school at 16 and joined Pfizer, the pharmaceutical and biomedical company, as a laboratory technician. At Pfizer she began working with the mass spectrometer which measures the mass of all the atoms in a particular sample. She studied for an ONC and HNC in Chemistry in the evenings and at weekends and later gained a PHD in Chemistry from Cambridge University.She was appointed DBE in 2013 for services to science and industry. In 2021 she founded the Kavli Institute for NanoScience Discovery, an interdisciplinary science institute dedicated to studying structures and materials at an ultra-small scale.Carol has three children from her first marriage and lives in Oxfordshire with her second husband David. DISC ONE: Girl on Fire - Alicia Keys DISC TWO: She's Leaving Home - The Beatles DISC THREE: Prokofiev: Romeo and Juliet Suite No. 2, Op. 64b: I. Montagues and Capulets - Dance of the Knights. Performed by London Symphony Orchestra, conducted by Claudio Abbado DISC FOUR: Sonnet - The Verve DISC FIVE: Wild Horses - The Rolling Stones DISC SIX: Golden Brown - The Stranglers DISC SEVEN: Stairway to Heaven - Led Zeppelin DISC EIGHT: The Scientist - Coldplay BOOK CHOICE: The Herbal Apothecary: 100 Medicinal Herbs and How to Use Them by JJ Pursell LUXURY ITEM: A portable mass spectrometer CASTAWAY'S FAVOURITE: Stairway to Heaven - Led ZeppelinPresenter Lauren Laverne Producer Paula McGinley

In this episode, MEDSURG Nursing Journal Editor Dr. Dottie Roberts talks with Donna Kurek, Chief Quality and Patient Experience Officer for OrthoVirginia in Richmond, Virginia, and Immediate Past President of the National Association of Orthopaedic Nurses. Kurek discusses the Movement Is Life initiative. Movement Is Life is a nonprofit, multidisciplinary coalition seeking to eliminate racial, ethnic, and gender disparities by promoting movement, which improves individuals' overall health and quality of life. The National Association of Orthopaedic Nurses partners with Movement Is Life to promote physical activity as a foundational pillar for lifelong wellness and advance musculoskeletal health through education and advocacy.Donna Kurek, MSN, RN, MHA, ONC, CMSRN, CPHQ, FNAON, is Chief Quality and Patient Experience Officer for OrthoVirginia in Richmond, Virginia. She is the immediate past president of the National Association of Orthopaedic Nurses and serves as the association's liaison to the Movement Is Life Coalition.  Dottie Roberts, EdD, MSN, MACI, RN, OCNS-C, CMSRN, CNE, FNAON, FAMSN, is a Contributing Faculty Member at Walden University in Minneapolis, Minnesota; a Nursing Online Faculty Member at Southern New Hampshire University in Manchester, New Hampshire; and Editor of MEDSURG Nursing Journal.Visit our new online journal platform at www.jannettipublications.comChoose what works best for you – purchase individual articles, or subscribe and access all MEDSURG Nursing articles, including archives from past years. Plus, NCPD assessments are FREE for individual subscribers or through the purchase of the NCPD article.For archived episodes of this podcast and to learn more about MEDSURG Nursing, visit the journal's website at www.medsurgnursing.net.© Jannetti Publications, Inc.Music selections by Scott Holmeshttp://www.scottholmesmusic.com

More than a thousand AI medical devices have FDA clearance, yet fewer than two percent of radiologists actually use them.In this episode, Steve sits down with Dr. Brian Anderson—CEO and co‑founder of the Coalition for Health AI—to unpack why trust, transparency, and regulation could make or break the next wave of AI‑powered medicine.We cover:

Te invitamos a conocer más sobre nuestro Centro de Cirugía Oncológica de Alta Especialidad en Hospital Galenia, un espacio diseñado para brindar atención quirúrgica especializada a pacientes con cáncer. Conoce cómo nuestro equipo médico, tecnología de última generación y enfoque humano trabajan juntos para ofrecer tratamientos seguros, efectivos y personalizados.Nuestros Doctores te invitan a escuchar el #podcast para conocer más del tema. ¡No te pierdas sus recomendaciones! ¡Disfruta del episodio 272 y continúa escuchando cada uno de nuestros #PodcastsMédicos preparados especialmente para ti!➡️ ENLACES DE INTERÉSOtros episodios de Actitud Saludable | Centro Neurológico del Hospital Galenia

Ocean careers are often imagined as adventurous and exciting, but what does it actually mean to work in the ocean every day, especially in the deep sea? In this episode of the How to Protect the Ocean podcast, Andrew speaks with Megan Paulson from Ocean Networks Canada, Josh Tedarenko from Campac Marine Services, and Dirk, who all work in partnership on deep-sea observatory operations and ROV missions. They share their unique experiences, challenges, and the incredible coordination required to operate in high-pressure ocean environments. Deep-sea technology plays a crucial role in their work—from deploying and maintaining underwater observatories to remotely operated vehicles (ROVs) capable of diving to 6,000 meters. You'll learn about the science, logistics, and passion behind careers that support ocean research and monitoring. Whether you're curious about marine tech, deep-sea exploration, or launching your own ocean science career, this episode will give you an insider's view of life under the surface. Website: https://www.oceannetworks.ca/ Join the Undertow: https://www.speakupforblue.com/jointheundertow Connect with Speak Up For Blue Website: https://bit.ly/3fOF3Wf Instagram: https://bit.ly/3rIaJSG TikTok: https://www.tiktok.com/@speakupforblue Twitter: https://bit.ly/3rHZxpc YouTube: www.speakupforblue.com/youtube    

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

Most medical care is backed by varying types of evidence, yet we apply higher standards to digital health tools before they're trusted, adopted, or reimbursed.In this special episode, guest host Lucia Savage is joined by Dr. Vindell Washington of Verily and Dr. Aaron Carroll of AcademyHealth for a candid conversation about the uneven standards we apply to digital versus traditional care. Together, they explore how we define evidence, whose voices shape that definition, and what it takes to build trust in an AI-powered healthcare future.We cover:

In this episode of the Real Health Podcast, we welcome back Dr. Kirsten West, ND, LAc, FABNO—an integrative oncology expert at Riordan Clinic—alongside special guest Jenn Nolan, BS, MS, ONC, TAP, owner and oncology nutrition consultant at Remission Nutrition. Together, they address your questions and share valuable insights from their experience supporting patients through integrative cancer care.Learn more about the hosts:•Dr. Kirsten West, ND, LAc, FABNO : https://riordanclinic.org/staff/kirsten-west-nd-lac-fabno/•Jen Nolan: https://www.remissionnutrition.com/jennolanRead the transcript:https://realhealthpodcast.orgLearn more about Riordan Clinic:https://riordanclinic.org/Interested in becoming a Patient:https://riordanclinic.org/request-an-appointment/*Disclaimer*The information contained on The Real Health Podcast and the resources mentioned are for educational purposes only. They are not intended as, and shall not be understood or construed as medical or health advice. The information contained on this podcast is not a substitute for medical or health advice from a professional who is aware of the facts and circumstances of your individual situation. Information provided by hosts and guests on The Real Health Podcast or the use of any products or services mentioned does not create a practitioner-patient relationship between you and any person affiliated with this podcast.

Ocean Networks Canada (ONC) began as a bold idea—to create a real-time, always-on listening system for the ocean. In this episode, Surfacing Secrets: Mavericks and Visionaries, we go behind the scenes with the people who made that idea real. From laying cables deep in the Pacific to building trust with research institutions and government partners, this is the untold story of how a world-leading ocean observatory came to life. Our guests—Kate Moran (President and CEO of Ocean Networks Canada), John Delaney (Professor Emeritus, School of Oceanography, University of Washington), and Benoit Pirenne (Corporate Innovation and Technology Officer at ONC)—share what it took to turn an ambitious vision into the ocean science infrastructure Canada relies on today. From early technical hurdles to moments of breakthrough, they reflect on the innovations, partnerships, and persistence that helped ONC become a global leader in ocean monitoring. If you care about ocean conservation, marine technology, or how visionary ideas turn into impact, this is a story you'll want to hear. The episode marks the beginning of a monthly series where I collaborate with Ocean Networks Canada and Balad'Eau podcast, where we explore the great work of ONC. Ocean Netorks Canada: https://www.oceannetworks.ca/   Follow a career in conservation: https://www.conservation-careers.com/online-training/ Use the code SUFB to get 33% off courses and the careers program.   Do you want to join my Ocean Community? Sign Up for Updates on the process: www.speakupforblue.com/oceanapp   Sign up for our Newsletter: http://www.speakupforblue.com/newsletter   Facebook Group: https://bit.ly/3NmYvsI Connect with Speak Up For Blue: Website: https://bit.ly/3fOF3Wf Instagram: https://bit.ly/3rIaJSG TikTok: https://www.tiktok.com/@speakupforblue Twitter: https://bit.ly/3rHZxpc YouTube: www.speakupforblue.com/youtube    

In this episode of the Real Health Podcast, we welcome back Dr. Kirsten West, ND, LAc, FABNO—an integrative oncology expert at Riordan Clinic—alongside special guest Jenn Nolan, BS, MS, ONC, TAP, owner and oncology nutrition consultant at Remission Nutrition. Together, they address your questions and share valuable insights from their experience supporting patients through integrative cancer care.Learn more about the hosts:•Dr. Kirsten West, ND, LAc, FABNO : https://riordanclinic.org/staff/kirsten-west-nd-lac-fabno/•Jen Nolan: https://www.remissionnutrition.com/jennolanRead the transcript:https://realhealthpodcast.orgLearn more about Riordan Clinic:https://riordanclinic.org/Interested in becoming a Patient:https://riordanclinic.org/request-an-appointment/*Disclaimer*The information contained on The Real Health Podcast and the resources mentioned are for educational purposes only. They are not intended as, and shall not be understood or construed as medical or health advice. The information contained on this podcast is not a substitute for medical or health advice from a professional who is aware of the facts and circumstances of your individual situation. Information provided by hosts and guests on The Real Health Podcast or the use of any products or services mentioned does not create a practitioner-patient relationship between you and any person affiliated with this podcast.

A la Quinta va la vencida. José Manuel Tejedor y Juan Yagüe. Pedro Subijana. Entrevista: Fernando Aguirregomezcorta, Oncólogo pediátrico.Escuchar audio

In this episode, you'll hear about the latest developments in tailoring cancer treatments to individual patients using Precision Oncology.  Two thought leaders, Simone Ndujiuba, a Clinical Oncology Pharmacist at Prime Therapeutics, and Karan Cushman, Head of Brand Experience and host of The Precision Medicine Podcast for Trapelo Health, discuss real-world research that is paving the way for Prime and our partners to help providers reduce turnaround times so patients can start treatment as soon as possible.  Join your host Maryam Tabatabai as they dig into this evolving topic of precision oncology. www.primetherapeuitics.com ⁠Chapters⁠Defining precision medicine (08:50)Evaluating real-world operational process of biomarker testing (14:36)Turnaround times are crucial (17:40)A patients view into the importance of time (24:39)Technology and process aid in time and process (29:30)Helping bridge knowledge gaps for providers and payers (33:55) The focus is on Precision Oncology right now (37:00)Precision medicine in other disease categories (40:09)Future of precision oncology is bright (42:07) References Singh, B.P., et al. (2019). Molecular profiling (MP) for malignancies: Knowledge gaps and variable practice patterns among United States oncologists (Onc). American Society of Clinical Oncology. https://meetings. asco.org/abstracts-presentations/173392 Evangelist, M.C., et al. (2023). Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study. Journal of Clinical Oncology, 41(Supplement 16). https://doi.org/10.1200/JCO.2023.41.16_suppl.9109. Ossowski, S., et al. (2022). Improving time to molecular testing results in patients with newly diagnosed, metastatic non-small cell lung cancer. Journal of Clinical Oncology, 18(11). https://doi.org/10.1200/OP.22.00260 Naithani N, Atal AT, Tilak TVSVGK, et al. Precision medicine: Uses and challenges. Med J Armed Forces India. 2021 Jul;77(3):258-265. doi: 10.1016/j.mjafi.2021.06.020.  Jørgensen JT. Twenty Years with Personalized Medicine: Past, Present, and Future of Individualized Pharmacotherapy. Oncologist. 2019 Jul;24(7):e432-e440. doi: 10.1634/theoncologist.2019-0054.  MedlinePlus. What is genetic testing? Retrieved on April 21, 2025 from https://medlineplus.gov/genetics/understanding/testing/genetictesting/. MedlinePlus. What is pharmacogenetic testing? Retrieved on April 21, 2025 from https://medlineplus.gov/lab-tests/pharmacogenetic-tests/#:~:text=Pharmacogenetics%20(also%20called%20pharmacogenomics)%20is,your%20height%20and%20eye%20color.  Riely GJ, Wood DE, Aisner DL, et al. National Cancer Comprehensive Network (NCCN) clinical practice guidelines: non-small cell lung cancer, V3.2005. Retrieved April 21, 2025 from https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.  Benson AB, Venook AP, Adam M, et al. National Cancer Comprehensive Network (NCCN) clinical practice guidelines: colon cancer, V3.2025. Retrieved April 21, 2025 from https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Rosenberg PS, Miranda-Filho A. Cancer Incidence Trends in Successive Social Generations in the US. JAMA Netw Open. 2024 Jun 3;7(6):e2415731. doi: 10.1001/jamanetworkopen.2024.15731. PMID: 38857048; PMCID: PMC11165384. Smeltzer MP, Wynes MW, Lantuejoul S, et al. The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. J Thorac Oncol. 2020 Sep;15(9):1434-1448. doi: 10.1016/j.jtho.2020.05.002.The views and opinions expressed by the guest featured on this podcast are their own and do not necessarily reflect the official policy or position of Prime Therapeutics LLC, its hosts, or its affiliates. The guest's appearance on this podcast does not imply an endorsement of their views, products, or services by Prime Therapeutics LLC. All content provided is for informational purposes only and should not be construed as professional advice.

Oncólogos denuncian presiones para no recetar fármacos caros contra el cáncer y ahorrar costes.

Send us a textInteroperability has long been a buzzword in healthcare In an ideal world, our healthcare system would exchange timely, high-quality data to empower patients, improve clinical quality, and keep costs under control. How close are we to making this a reality?In this episode of the HealthBiz Podcast, host David E Williams talks with Dr. Donald Rucker, Chief Strategy Officer at 1upHealth, about how their health data management platform is transforming the way healthcare organizations access, share, and leverage patient data to improve outcomes, enhance efficiency, and drive more personalized care.TOPICS(0:25) Introduction(0:52) How Dr. Donald Rucker Got Into Healthcare(2:54) Rucker's Educational Path and Career(11:14) What Does 1upHealth Do?(21:13) Why Are CMS APIs So Important?(25:15) How Do APIs Affect Prior Authorization?(31:37) Book Recommendations from Dr. Donald Rucker

El Día Mundial de la lucha contra el Cáncer Infantil fue establecido en el año 2002 por la Organización Internacional de Cáncer Infantil, con el objetivo de crear conciencia y sensibilizar sobre esta enfermedad que afecta a muchas niñas, niños y adolescentes en el mundo. También busca promover la detección oportuna, para incrementar las posibilidades de recuperación y mejorar la calidad de vida en las y los menores. En este podcast de El Expresso de las 10 escucha las voces del Dr. Fernando Sánchez Zubieta, Médico Oncólogo, Fundador y Jefe del Servicio Hematología-Oncología Pediátrica Hospital Civil de Guadalajara Con sede en el Nuevo Hospital Civil Dr. Juan I. Menchaca, quien nos brinda orientación en torno a la detección, atención y tratamiento de Cáncer Infantil. Además de Leticia Casillas González y Anabel López en vivo y a Alejandro Villanueva y Everardo González en grabación; quienes nos comparten sus historias de esperanza…

About Erin Weber:Erin Richter Weber is a healthcare leader with 14 years at CAQH. She oversees CAQH CORE, advancing healthcare automation, and CAQH Insights, producing the annual Index report. Erin unites stakeholders to address industry challenges through data-driven innovation. Previously, she consulted for PwC and led research at the Advisory Board Company. She holds a Master's from Harvard and a Bachelor's from Cornell, making her a pivotal voice in healthcare standards and policy.About Don Rucker:Dr. Donald Rucker is the Chief Strategy Officer of 1upHealth and former National Coordinator for Health IT at HHS (2017–2021). He led the ONC's 21st Century Cures Act Interoperability Rule, enabling secure patient access to health data via standardized FHIR APIs. A board-certified physician with clinical informatics expertise, he co-developed the first Windows-based electronic medical record. Dr. Rucker holds degrees from Harvard, the University of Pennsylvania, and Stanford, blending medicine, technology, and leadership.Things You'll Learn:Provider data is the backbone of the healthcare system, powering everything from patient care to billing, and requires standardization to ensure accuracy.The healthcare industry needs to learn from the internet and establish a system similar to domain name services to reduce friction.Data quality is paramount for interoperability, requiring standardized definitions of data elements like location. To improve data, AI should be included. AI can be used to standardize the multiple sources of provider data by merging them and enhancing the quality of that data. The healthcare industry is behind other industries, and boldness comes from adopting solutions that have already been implemented elsewhere. Resources:Connect with and follow Erin Weber on LinkedIn.Follow CAQH on LinkedIn and visit their website.Connect with and follow Don Rucker on LinkedIn.Learn more about 1upHealth on their LinkedIn and website.Check out the latest annual CAQH Index Report here. 

For the past 20 years, under both Republican and Democratic administrations, the ONC has played a pivotal role shaping and regulating the health tech market. On the eve of the election, Micky Tripathi joined me to discuss the agency's recently expanded role. Now, two months later—though it feels like a decade—the future is uncertain. Will the ONC and ASTP continue as market regulators and opportunity catalysts, or is a new direction on the horizon?Here's what we covered:The government's role in shaping and regulating the health tech ecosystemAI in healthcare: balancing the risks of misuse vs. the risk of “missed uses” Health information sharing: why Micky is optimistic about the future Can technology take the pain out of prior auth?Micky thinks we are standing on the edge of a transformative era:“We are just at the beginning of the most exciting decade...health information technology can really start to show… the return on investment for patients. We've done a lot of hard work over the last 10 years… [With that foundation in place] we have the opportunity to say there's an ROI here for patients.”Relevant LinksBlog post on ONC reorganization: ONC's Next ChapterTEFCA overviewForbes interview: Where is interoperability headed?Healthcare Dive: HHS AI Task Force Takes Shape (March 2024)Blog post by Micky: Getting real about information blocking and APIs (October 2024)About Our GuestMicky Tripathi is the Assistant Secretary for Technology Policy, National Coordinator for Health Information Technology, and Acting Chief Artificial Intelligence Officer at the U.S. Department of Health and Human Services, where he leads the formulation of HHS technology and data strategy and coordinates technology policies, standards, programs, and investments.Dr. Tripathi has over 20 years of experience across the health IT landscape. Prior to joining the federal government he served as Chief Alliance Officer for Arcadia, a health care data and software company focused on population health management and value-based care, the project manager of the Argonaut Project, an industry collaboration to accelerate the adoption of FHIR, and a board member of HL7, the Sequoia Project, the CommonWell Health Alliance, and the CARIN Alliance.Dr. Tripathi served as the President and Chief Executive Officer of the Massachusetts eHealth Collaborative (MAeHC), a non-profit health IT advisory and clinical data analytics company. He was also the founding President and CEO of the Indiana Health Information Exchange, a statewide HIE partnered with the Regenstrief Institute, an Executive Advisor to investment firm LRVHealth, and a Fellow at the Berkman-Klein Center for Internet and Society at Harvard University.He holds a PhD in political science from the Massachusetts...

Shutdown..... AVERTED Mergers - Auto Industry big move Lots of Trump Talk The Market's new favorite stocks PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter DONATIONS ? Thank you for all who gave to the Thanksgiving Holiday Campaign... Warm-Up - Shutdown..... AVERTED - Mergers - Auto Industry big move - Lots of Trump Talk - Deli Stock Scheme - Update - Holiday Tidings! - Markets - S&P 500 Equal weight down 6% MTD, Small Caps down 8% - The New favs? Quantum Computing Stocks - Santa Like them..... - Index inclusion has become a thing Checking out the early CTP Cup Standings EVERYONE IS IN! - 7 Contestants.... Fed Meeting Dec 18th - Fed freaked out markets - All of a sudden they are projecting that inflation is not going to come down to their 2% level into 2026 - DJIA was donw 1000 points and it was an ugly day overall. - Onc day later, PCE comes out not too far aay from assumptions and market takes off - Just goes to show that DJIA - Records? - Follow up - it was 10 days and the last time that happened was 1974 Meanwhile - XMAS Rally - Once big day down, then a test and BOUNCE - Most of the Fed Day losses have been wipe out - still much damage in December --- Once again - Mega cap holding things up ---- EVEN though 10Yr >4.6%  - this is an important price point... Failed  couple of times before. Quantum Computing Stocks - Ever since Alphabet (Google) announced that they made progress, been some crazy moves on a few names - with YTD returns -- D-Wave Quantum Inc  QBTS  (825%) -- Rigetti Computing Inc   RGTI  (1,050%) -- Quantum Computing Inc   QUBT  (1,900%) -- Defiance Quantum ETF   QTUM (51%) -- IONQ Inc    IONQ   (240%) ---(none seem to be making any money  - actually losing a ton) More Quantum - Willow's speed is almost incomprehensible — according to Google, it's able to perform a computation in under five minutes that would take one of today's fastest supercomputers 10 septillion years to solve. Ten septillion is 10,000,000,000,000,000,000,000,000 years. - Concern has turned to the potential for this technology to break down crypto (or other) cryptography. --- It may take years - but this could be something we need to watch as a byproduct, the need for better security from quantum hacks Auto Merger - Japanese automakers Nissan and Honda on Monday announced they had entered into official talks to merge and create the world's third-largest automaker by sales. - The deal would aim to share intelligence and resources and deliver economies of scale and synergies while protecting both brands - Nissan's strategic partner Mitsubishi has been offered the chance to join the new group and will take a decision by the end of January 2025. - Lots of things to iron out before this deal gets done Index Traders - Hang on... - Huge moves to reset these days - Companies are competing to get to NASDAQ and NYSE to gain inclusion as they know share prices will potentially pop - Palatntir is banking on that as they said in their recent announcement and one reason was to get inclusion in the NASDAQ 100 - These kind of index changes has buig impacts on stocks - - ALSO, there should be some movement over the next month as there will be re-balancing going on as 2024 big run for markets/stocks Trump Talk/Plans - Trump said he will not let the canal fall into the 'wrong hands' - Trump accused Panama of charging excessive fees to use the canal - Panama's President Mulino defends canal's independence and fees - US handed over control of the canal in 1999 - Talk that we could take it back - Twitter: "Every square meter of the Panama Canal and the surrounding area belongs to Panama and will c...

Host Dr. Jay Anders invites back Micky Tripathi, PhD, MPP, the current Assistant Secretary for Technology Policy, National Coordinator for Health Information Technology, and Acting Chief Artificial Intelligence Officer for a look back and forward for the ONC. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Matt Lowe, MDiv, MSN, APRN, FNP-C, ONC is joined by Jimmy Dascani and Dan Veronie from Arthrex, a medical device company and leader in new product development and medical education in orthopedics. Jimmy is a licensed RN and the Healthcare Administrator Relations Director for Arthrex. Dan is a PA and serves as the Senior Clinical Specialist with Arthrex. They talk about Arthex's new product, OrthoPedia, a free web-based platform designed for clinicians, academics and patients for all things orthopedic surgery education. Jimmy and Dan share their insights on the development of OrthoPedia, and how it is changing the game in the way healthcare providers and patients can easily access orthopaedic education at any level.

Dr. Ryan Augustin and Dr. Jason Luke discuss neoadjuvant immunotherapy and the importance of multidisciplinary team coordination, promising new TIL therapy for advanced melanoma, and the emerging role of CD3 engagers in treatment strategies. TRANSCRIPT Dr. Ryan Augustin: Hello, I'm Dr. Ryan Augustin, your guest host of the ASCO Daily News Podcast today. I'm a medical oncology fellow at Mayo Clinic in Rochester, Minnesota. Joining me today is Dr. Jason Luke, an associate professor of medicine and the director of the Cancer Immunotherapeutic Center at the University of Pittsburgh Hillman Cancer Center. I had the privilege of working as a postdoc in Jason's translational bioinformatics lab, where we investigated mechanisms of resistance to immunotherapy in melanoma and other cancers.  Today, we'll be discussing 3 important topics, including neoadjuvant immunotherapy and the importance of multidisciplinary team coordination, the impact and practical considerations for incorporating TIL therapy into melanoma, and the current and future use of CD3 engagers in both uveal and cutaneous melanoma.  You'll find our full disclosures in the transcript of this episode.  Jason, it's great to have this opportunity to speak with you today. Dr. Jason Luke: Absolutely. Thanks, Ryan. It's great to see you. Dr. Ryan Augustin: So, to kick things off, Jason, we, of course, have seen tremendous advances in cancer immunotherapy, not only in metastatic disease but also the perioperative setting. Recent data have shown that the use of neoadjuvant therapy can provide not only critical prognostic information but can also help individualize post-resection treatment strategies and potentially even eliminate adjuvant therapy altogether in patients who achieve a pathologic, complete response. This signifies a conceptual shift in oncology with the goal of curing patients with immunotherapy. In triple-negative breast cancer, the KEYNOTE-522 regimen with pembrolizumab is standard of care. In non-small cell lung cancer, there are now four FDA approved chemo-IO regimens in both the neoadjuvant and perioperative settings. And, of course, in melanoma, starting with SWOG S1801 utilizing pembro mono therapy, and now with combined CTLA-4 PD-1 blockade based on results from the NADINA trial, neoadjuvant IO is the new standard of care in high-risk, resectable melanoma. It's important to highlight this because whereas other tumor types have more mature multidisciplinary care, for example, patients with breast cancer are reviewed by the whole team in every center, and every patient with lung cancer certainly benefits from multidisciplinary care conferences, that's not always the case with melanoma, given the relative frequency of cases compared to other tumor types.  Jason, would you say that we have now moved into an era where the integration of a multidisciplinary team and melanoma needs to be prioritized. And why is it important to have multidisciplinary team coordination from the onset of a patient's diagnosis? Dr. Jason Luke: Well, I think those are great questions, Ryan, and I think they really speak to the movement in our field and the great success that we've had integrating systemic therapy, particularly immunotherapy, into our treatment paradigms. And so, before answering your question directly, I would add even a little bit more color, which is to note that over the last few years, we've additionally seen the development of adjuvant therapy into stages of melanoma that, historically speaking, were considered low-risk, and medical oncologists might not even see the patient. To that, I'm speaking specifically about the stage 2B and 2C approvals for adjuvant anti-PD-1 with pembrolizumab or nivolumab. So this has been an emerging complication.  Classically, patients are diagnosed with melanoma by either their primary care doctor or a dermatologist. Again, classically, the next step was referral to a surgeon who had removed the primary lesion, with discussion around nodal evaluation as well. And that paradigm has really changed now, where I think integration of medical oncology input early on in the evaluation of the appropriate treatment plan for patients with melanoma is quite a pressing issue now, both because we have FDA approvals for therapeutics that can reduce risk of recurrence, and whether or not to pursue those makes a big difference to the patient for discussion early on.  And, moreover, the use of systemic therapies now, prior to surgery, of course, then, of course, requires the involvement of medical oncology. And just for an emphasis point on this, it's classically the case, for good reason, that surgeons complete their surgery and then feel confident to tell the patient, “Well, we got it all, and you're just in really good shape.” And while I understand where that's coming from, that often leaves aside the risk of recurrence. So you can have the most perfect surgery in the world and yet still be at very high risk of recurrence. And so it's commonly the case that we get patients referred to us after surgery who think they're just in totally good shape, quite surprised to find out that, in fact, they might have a 20% to 50% risk of recurrence. And so that's where this multidisciplinary integration for patient management really does make a big difference.  And so I would really emphasize the point you were making before, which is that we need multidisciplinary teams of med onc with derm, with surgery early on, to discuss “What are the treatment plans going to be for patients?” And that's true for neoadjuvant therapy, so, for palpable stage 3, where we might give checkpoint inhibitors or combinations before surgery. But it's true even in any reasonably high-risk melanoma, and I would argue in that state, anything more than stage 1 should be discussed as a group, because that communication strategy with the patient is so important from first principles, so that they have an expectation of what it's going to look like as they are followed out over time. And so we're emphasizing this point because I think it's mostly the case at most hospitals that there isn't a cutaneous oncology disease management meeting, and I think there needs to be.  It's important to point out that usually the surgeons that do this kind of surgery are actually either the GI surgeons who do colon cancer or the breast surgeons. And so, given that melanoma, it's not the most common kind of cancer, it could easily be integrated into the existing disease review groups to review these cases. And I think that's the point we really want to emphasize now. I think we're not going to belabor the data so much, but there are enormous advantages to either perioperative or adjuvant systemic therapy in melanoma. We're talking about risk reduction of more than 50%, 50-75% risk reduction. It's essential that we make sure we optimally offer that to patients. And, of course, patients will choose what they think is best for their care. But we need to message to them in a way that they can understand what the risks and benefits of those treatments are and then are well set up to understand what that treatment might look like and what their expectations would be out over time.  So I think this is a great art of medicine place to start. Instead of belaboring just the details of the trial to say, let's think about how we take care of our patients and how we communicate with them on first principles so that we can make the most out of the treatments that we do have available. Dr. Ryan Augustin: That's great, Jason. Very insightful points. Thank you.  So, shifting gears now, I'd also like to ask you a little bit about TIL therapy in melanoma. So our listeners will be aware that TIL is a promising new approach for treating advanced melanoma and leverages the power of a patient's cytotoxic T cells to attack cancer cells. While we've known about the potential of this therapy for some time, based on pioneering work at the NCI, this therapy is now FDA approved under the brand AMTAGVI (Lifileucel) from Iovance Biotherapeutics, making it the first cellular therapy to be approved for a solid tumor. Now, I know TIL therapy has been administered at your institution, Jason, for several years now, under trial status primarily for uveal melanoma using an in-house processing. But for many cancer centers, the only experience with cellular therapy has come under the domain of malignant hematology with CAR T administration. At our institution, for example, we have only recently started administering TIL therapy for melanoma, which has required a tremendous multidisciplinary effort among outpatient oncology, critical care, and an inpatient hematology service that has expertise in cytokine release syndrome.  Jason, where do you see TIL therapy fitting into the metastatic space? Which patients do you think are truly candidates for this intensive therapy? And what other practical or logistical considerations do you think we should keep in mind moving forward? Dr. Jason Luke: Well, thanks for raising this. I think the approval of lifileucel, which is the scientific name for the TIL product that's on the market now. It really is a shift, a landscape shift in oncology, and we're starting in melanoma again, as seems to be commonly the case in drug development. But it's really important to understand that this is a conceptually different kind of treatment, and therefore, it does require different considerations. Starting first with data and then actualization, maybe secondarily, when we see across the accelerated approval package that led to this being available, we quote patients that the response rate is likely in the range of 30%, maybe slightly lower than that, but a meaningful 25% to 30% response rate, and that most of those patients that do have response, it seems to be quite durable, meaning patients have been followed up to four years, and almost all the responders are still in response. And that's a really powerful thing to be able to tell a patient, particularly if the patient has already proceeded through multiple lines of prior standard therapy. So this is a very, very promising therapy.  Now, it is a complicated therapy as well. And so you highlighted that to do this, you have to have a tumor that's amenable for resection, a multidisciplinary team that has done a surgery to remove the tumor, sent it off to the company. They then need to process the TIL out of the tumor and then build them up into a personalized cell product, bring it back, you have to lympho-deplete the patient, re-introduce this TIL. So this is a process that, in the standard of care setting under best circumstances, takes roughly six weeks. So how to get that done in a timely fashion, I think, is evolving within our paradigms. But I think it is very important for people who practice in settings where this isn't already available to realize that referring patients for this should be a strong consideration. And thinking about how you could build your multidisciplinary team in a way to be able to facilitate this process, I think is going to be important, because this concept of TIL is relevant to other solid tumors as well. It's not approved yet in others, but we kind of assume eventually it probably will be. And so I think, thinking through this, how could it work, how do you refer patients is very important.  Now, coming back to the science, who should we treat with this? Well, of course, it's now an air quotes “standard of care option”, so really it ought to be available to anybody. I will note that currently, the capacity across the country to make these products is not really adequate to treat all the patients that we'd want. But who would we optimally want to treat, of course, would be people who have retained a good performance status after first line therapy, people who have tumors that are easily removable and who have not manifested a really rapid disease progression course, because then, of course, that six-week timeline probably doesn't make sense. The other really interesting data point out of the clinical trials so far is it has looked like the patients who got the least amount of benefit from anti-PD-1 immunotherapy, in other words, who progressed immediately without any kind of sustained response, those patients seem to have the best response to TILs, and that's actually sort of a great biomarker. So, this drug works the best for the population of patients where checkpoint inhibitors were not effective. And so as you think about who those patients might be in your practice, as you're listening, I think prioritizing it for primary progression on anti PD-1, again and giving it ahead thought about how would you get the patient through this process or referred to this process very quickly is really important because that lag time is a problem. Patients who have melanoma tend to progress reasonably quickly, and six weeks can be a long time in melanoma land. So, thinking ahead and building those processes is going to be important moving into the future Dr. Ryan Augustin: Definitely appreciate those practical considerations. Jason, thank you.  Moving on to our final topic, I was hoping to discuss the use of immune cell engagers in melanoma. So, similar to CAR T therapy, bispecific T-cell engagers, or BiTEs, as they're commonly known, are standard of care in refractory myeloma and lymphoma. But these antibodies engaging CD-3 on T cells and a tumor specific antigen on cancer cells are relatively new in the solid tumor space. Tarlatamab, which is a DLL-3 and CD-3 bispecific antibody, was recently approved in refractory small cell lung cancer, and, of course, tebentafusp, an HLA-directed CD-3 T cell engager was approved in uveal melanoma in 2022. Both T and NK cell engaging therapies are now offering hope in cancers where there has historically been little to offer. However, similar to our discussion with TIL therapy, bispecifics can lead to CRS and neurotoxicity, which require considerable logistical support and care coordination.  Jason, I was wondering if you could briefly discuss the current landscape of immune cell engagers in melanoma and how soon we may see these therapies enter the treatment paradigm for cutaneous disease. Dr. Jason Luke: I think it is an exciting, novel treatment strategy that I think we will only see emerge more and more. You alluded to the approval of tebentafusp in uveal melanoma, and those trials were, over the course of a decade, where those of us in solid tumor land learned how to manage cytokine release syndrome or the impact of these C3 bispecifics, in a way that we weren't used to. And what I'll caution people is that CRS, as this term, it sounds very scary because people have heard of patients that, of course, had difficult outcomes and hematological malignancies, but it's a spectrum of side effects. And so, when we think about tebentafusp, which is the approved molecule, really what we see is a lot of rash because GP100, the other tumor antigen target, is in the skin. So, patients get a rash, and then people do get fevers, but it's pretty rare to get more than that. So really what you have to have is the capacity to monitor patients for 12 hours, but it's really not more scary than that. So it really just requires treating a few people to kind of get used to these kinds of symptoms, because they're not the full-on ICU level CRS that we see with, say, CAR T-cells.  But where is the field going? Well, there's a second CD3 bispecific called brenetafusp that targets the molecule PRAME, that's in a phase 3 clinical trial now for frontline cutaneous melanoma. And tebentafusp is also being evaluated in cutaneous melanoma for refractory disease. So, it's very possible that these could be very commonly used for cutaneous melanoma, moving into, say, a two-to-four-year time horizon. And so therefore, getting used to what are these side effects, how do you manage them in an ambulatory practice for solid tumor, etc., is going to be something everyone's going to have to learn how to deal with, but I don't think it should be something that people should be afraid of.  One thing that we've seen with these molecules so far is that their kinetics of treatment effect do look slightly different than what we see with more classic oncology therapies. These drugs have a long-term benefit but doesn't always manifest as disease regression. So, we commonly see patients will have stable disease, meaning their tumor stops growing, but we don't see that it shrank a lot, but that can turn into a very meaningful long-term benefit. So that's something that we're also, as a community, going to have to get used to. It may not be the case we see tumors shrink dramatically upfront, but rather we can actually follow people with good quality- of-life over a longer period of time.  Where is the field going? You mentioned tarlatamab in small cell lung cancer, and I think we're only going to see more of these as appropriate tumor antigens are identified in different tumors. And then the other piece is these CD3 engagers generally rely upon some kind of engagement with a T cell, whether CD3 engagers, and so they can be TCR or T-cell receptor-based therapies, although they can be also SCFV-based. But that then requires new biomarkers, because TCR therapy requires HLA restriction. So, understanding that now we're going to need to profile patients based on their germline in addition to the genomics of the tumor. And those two things are separate. But I would argue at this point, basically everybody with cutaneous melanoma should be being profiled for HLA-A(*)0201, which is the major T-cell receptor HLA haplotype that we would be looking for, because whether or not you can get access immediately to tebentafusp, but therefore clinical trials will become more and more important.  Finally, in that T-cell receptor vein, there are also T cell receptor-transduced T cells, which are also becoming of relevance in the oncology community and people listening will be aware in synovial sarcoma of the first approval for a TCR-transduced T cell with afamitresgene autoleucel. And in melanoma, we similarly have TCR-transduced T cells that are coming forward in clinical trials into phase 3, the IMA203 PRAME-directed molecule particularly. And leveraging our prior conversation about TILs, we're going to have more and more cellular based therapies coming forward, which is going to make it important to understand what are the biomarkers that go with those, what are the side effect profiles of these, and how do you build your practice in a way that you can optimally get your patients access to all of these different treatments, because it will become more logistically complicated, kind of as more of these therapies come online over the next, like we said, two to four years kind of time horizon. So, it's very exciting, but there is more to do, both logistically and scientifically. Dr. Ryan Augustin: That's excellent. Thanks, Jason, and thank you so much for sharing your great insight with us today on the ASCO Daily News Podcast. Dr. Jason Luke: Thanks so much for the opportunity. Dr. Ryan Augustin: And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode, and you can follow Dr. Luke on X, formerly known as Twitter, @jasonlukemd. And you can find me, @RyanAugustinMD. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers: @ryanaugustinmd Dr. Jason Luke @jasonlukemd   Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn   Disclosures: Dr. Ryan Augustin: No relationships to disclose Dr. Jason Luke: Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof) Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

Artificial intelligence continues to gain popularity as society identifies its uses and benefits. AI has shown promise despite being in the early phases of implementation in sarcoma care. For this episode we discuss Artificial intelligence, its present and the future in sarcoma care. Bozzo A, Tsui JMG, Bhatnagar S, Forsberg J. Deep Learning and Multimodal Artificial Intelligence in Orthopaedic Surgery. J Am Acad Orthop Surg. 2024 Jun 1;32(11):e523-e532. Bozzo, A., Hollingsworth, A., Chatterjee, S. et al. A multimodal neural network with gradient blending improves predictions of survival and metastasis in sarcoma. npj Precis. Onc. 8, 188 (2024). sarcomaAIhub.com Find out More about our Doctors: Dr. Izuchukwu Ibe: www.linkedin.com/in/izuchukwu-ibe-a073537a/ Dr. Elyse Brinkmann: www.linkedin.com/in/elyse-brinkmann/

Reed Smith partners share insights about U.S. Department of Health and Human Services initiatives to stave off misuse of AI in the health care space. Wendell Bartnick and Vicki Tankle discuss a recent executive order that directs HHS to regulate AI's impact on health care data privacy and security and investigate whether AI is contributing to medical errors. They explain how HHS collaborates with non-federal authorities to expand AI-related protections; and how the agency is working to ensure that AI outputs are not discriminatory. Stay tuned as we explore the implications of these regulations and discuss the potential benefits and risks of AI in healthcare.  ----more---- Transcript: Intro: Hello, and welcome to Tech Law Talks, a podcast brought to you by Reed Smith's Emerging Technologies Group. In each episode of this podcast, we will discuss cutting-edge issues on technology, data, and the law. We will provide practical observations on a wide variety of technology and data topics to give you quick and actionable tips to address the issues you are dealing with every day.  Wendell: Welcome to our new series on AI. Over the coming months, we'll explore the key challenges and opportunities within the rapidly evolving AI landscape. Today, we will focus on AI in healthcare. My name is Wendell Bartnick. I'm a partner in Reed Smith's Houston office. I have a degree in computer science and focused on AI during my studies. Now, I'm a tech and data lawyer representing clients in healthcare, including providers, payers, life sciences, digital health, and tech clients. My practice is a natural fit given all the innovation in this industry. I'm joined by my partner, Vicki Tankle.  Vicki: Hi, everyone. I'm Vicki Tankle, and I'm a digital health and health privacy lawyer based in Reed Smith's Philadelphia office. I've spent the last decade or so supporting health industry clients, including healthcare providers, pharmaceutical and medical device manufacturers, health plans, and technology companies navigate the synergies between healthcare and technology and advising on the unique regulatory risks that are created when technology and innovation far outpace our legal and regulatory frameworks. And we're oftentimes left managing risks in the gray, which as of today, July 30th, 2024, is where we are with AI and healthcare. So when we think about the use of AI in healthcare today, there's a wide variety of AI tools that support the health industry. And among those tools, a broad spectrum of the use of health information, including protected health information, or PHI, regulated by HIPAA, both to improve existing AI tools and to develop new ones. And if we think about the spectrum as measuring the value or importance of the PHI, the individuals individuals identifiers themselves, it may be easier to understand that the far ends of the spectrum and easier to understand the risks at each end. Regulators in the industry have generally categorized use of PHI in AI into two buckets, low risk and high risk. But the middle is more difficult and where there can be greater risk because it's where we find the use or value of PHI in the AI model to be potentially debatable. So on the one hand of the spectrum, for example, the lower risk end, there are AI tools such as natural language processors, where individually identifiable health information is not centric to the AI model. But instead, for this example, it's the handwritten notes of the healthcare professional that the AI model learns from. And with more data and more notes, the tool's recognition of the letters themselves, not the words the letters form, such as patient's name, diagnosis, or lab results, the better the tool operates. Then on the other hand of the spectrum, the higher risk end, there are AI tools such as patient-facing next best action tools that are based on an individual's patient medical history, their reported symptoms, their providers, their prescribed medications, potentially their physiological measurements, or similar information, and they offer real-time customized treatment plans with provider oversight. Provider-facing clinical decision support tools similarly support the diagnosis and treatment of individual patients based on individual's information. And then in the middle of the spectrum, we have tools like hospital logistics planners. So think of tools that think about when the patient was scheduled for an x-ray, when they were transported to the x-ray department, how long did they wait before they got the x-ray, and how long after they received the x-ray were they provided with the results. These tools support population-based activities that relate to improving health or reducing costs, as well as case management and care coordination, which begs the question, do we really need to know that patient's identity for the tool to be useful? Maybe yes, if we also want to know the patient's sex, their date of birth, their diagnosis, date of admission. Otherwise, we may want to consider whether this tool can be done and be effective without that individually identifiable information. What's more is that there's no federal law that applies to the use of regulated health data in AI. HIPAA was first enacted in 1996 to encourage healthcare providers and insurers to move away from paper medical and billing records and to get online. And so when HIPAA has been updated over the years, the law still remains outdated in that it does not contemplate the use of data to develop or improve AI. So we're faced with applying an old statute to new technology and data use. Again, operating in a gray area that's not uncommon in digital health or for our clients. And to that end, there are several strategies that our HIPAA-regulated clients are thinking of when they're thinking of permissible ways to use PHI in the context of AI. So treatment, payment, healthcare operations activities for covered entities, proper management and administration for business associates, certain research activities and individual authorizations, or de-identified information are all strategies that our clients are currently thinking through in terms of permissible uses of PHI in AI. Wendell: So even though HIPAA hasn't been updated to apply directly to AI, that doesn't mean that HHS has ignored it. So AI, as we all know, has been used in healthcare for many years. And in fact, HHS has actually issued some guidance previously. Under the White House's Executive Order 14110, back in the fall of 2023, which was called Safe, secure, and trustworthy development and use of artificial intelligence, jump-started additional HHS efforts. So I'm going to talk about seven items in that executive order that apply directly to the health industry, and then we'll talk about what HHS has done since this executive order. So first, the executive order requires the promotion of additional investment in AI, and just to help prioritize AI projects, including safety and privacy and security. The executive order also requires that HHS create an AI task force that is supposed to meet and create a strategic plan that covers several topics with AI, including AI-enabled technology, long-term safety and real-world performance monitoring, equity principles, safety, privacy, and security, documentation, state and local rules, and then promotion of workplace efficiency and satisfaction. faction. Third, HHS is required to establish an AI safety program that is supposed to identify and track clinical errors produced by AI and store that in a centralized database for use. And then based on what that database contains, they're supposed to propose recommendations for preventing errors and then avoiding harms from AI. Fourth, the executive order requires that all federal agencies, including HHS, focus on increasing compliance with existing federal law on non-discrimination. Along with that includes education and greater enforcement efforts. Fifth, HHS is required to evaluate the current quality of AI services, and that means developing policies and procedures and infrastructure for overseeing AI quality, including with respect to medical devices. Sixth, HHS is required to develop a strategy for regulating the use of AI in the drug development process. Of course, FDA has already been regulating this space for a while. And then seventh, the executive order actually calls on Congress to pass a federal privacy law. But even without that, HHS's AI task force is including privacy and security, as part of its strategic plan. So given those seven requirements really for HHS to cover, what have they done since the fall of 2023? Well, as the end of July 2024, HHS has created a funding opportunity for applicants to receive money if they develop innovative ways to evaluate and improve the quality of healthcare data used by AI. HHS has also created the AI task force. And many of our clients are asking us, you know, about AI governance. What can they do to mitigate risk from AI? And HHS has, the task force has issued a plan for state, local, tribal, and territorial governments related to privacy, safety, security, bias, and fraud. And even though that applies to the public sector, Our private sector clients should take a look at that so that they know what HHS is thinking in terms of AI governance. Along with this publication, NIST also produces several excellent resources that companies can use to help them with their AI governance journey. Also important is that HHS has recently restructured internally to try to consolidate HHS's ability to regulate technology and areas connected to technology and place that under ONC. And ONC, interestingly enough, has posted job postings for a chief AI officer, a chief technology officer, and a chief data officer. So we would expect that once those roles are filled, they will be highly influential in how HHS looks at AI, both internally and then also externally, and how it will impact the strategic thinking and position of HHS going forward with respect to AI. Our provider and tech clients have also been interested in how AI and what HHS is saying affects certified health IT. And earlier this year, actually, ONC published the HTI-1 rule, which, among other things, is establishes transparency requirements for AI that's offered in connection with certified health IT. And that rule, the compliance deadline for that rule is December 31st of this year. HHS has also been involved in focusing on non-discrimination just as the executive order requires. And so our clients are asking, can they use AI for certain processes and procedures? And in fact, it appears that HHS strongly endorses the use of AI in technology, improving patient outcomes, etc. They've certainly not published anything that says AI should not be used. And in fact, CMS issued a final rule this year and FAQs that clarify that AI can be used to process claims under Medicare Advantage plans, as long as there's human oversight and all other laws are compliant. So there is no indication at all from HHS that using AI is somehow prevented or companies should be worried about using it as long as they comply with existing law. So after the White House executive order in the fall of 2023, HHS has a lot of work to do. They've done some, but there's still a lot to do related to AI. And we should expect more guidance and activity in the second half of 2024.  Outro: Tech Law Talks is a Reed Smith production. Our producers are Ali McCardell and Shannon Ryan. For more information about Reed Smith's Emerging Technologies Practice, please email techlawtalks@reedsmith.com. You can find our podcasts on Spotify, Apple Podcasts, Google Podcasts, reedsmith.com, and our social media accounts.  Disclaimer: This podcast is provided for educational purposes. It does not constitute legal advice and is not intended to establish an attorney-client relationship, nor is it intended to suggest or establish standards of care applicable to particular lawyers in any given situation. Prior results do not guarantee a similar outcome. Any views opinions or comments made by any external guest speaker are not to be attributed to Reed Smith LLP or its individual lawyers.  All rights reserved. Transcript is auto-generated.

Hosts Colin Hung and John Lynn discuss: Ripped from the Headlines: Crowdstrike, ONC, Biden/Trump, and the Olympics To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Get ahead of the competition with highlights from the GOAT of Social Media — Jen Gore. Hear Jennifer live at PIMCON, the first-ever PIM Conference September 15 - 17 | The Phoenician | Scottsdale, AZ Website: Pimcon.org  Code for $200 off: PIMJEN Welcome to Gold Medal Moments on Personal Injury Mastermind, a special mini-series that highlights Chris' favorite lessons from former PIM guests.  Each of these trailblazers and thought leaders will speak live at the inaugural PIMCon, the inaugural Personal Injury Mastermind Conference.  Social Media is no longer optional. It is essential if you want leads. Creating engaging, informative content on these platforms allows you to reach a wider audience, showcase your expertise, and build trust with potential clients. Jennifer Gore knows how to do it right. The GOAT of Social media has built her law firm, Atlanta Personal Injury Law Group, into one of the fastest-growing firms in the country - securing a place on the Onc. 5000 three years in a row.  And social media has been a key driver of that success. She's mastered the art of identifying her target demographic and tailoring her content to their interests and pain points. Press play to learn how you can apply her hard-won lessons to your firm.   Past Guests Past guests on Personal Injury Mastermind: Brent Sibley, Sam Glover, Larry Nussbaum, Michael Mogill, Brian Chase, Jay Kelley, Alvaro Arauz, Eric Chaffin, Brian Panish, John Gomez, Sol Weiss, Matthew Dolman, Gabriel Levin, Seth Godin, David Craig, Pete Strom, John Ruhlin, Andrew Finkelstein, Harry Morton, Shay Rowbottom, Maria Monroy, Dave Thomas, Marc Anidjar, Bob Simon, Seth Price, John Gomez, Megan Hargroder, Brandon Yosha, Mike Mandell, Brett Sachs, Paul Faust, Jennifer Gore-Cuthbert Additional Episodes You Might Enjoy 80. Mike Papantonio, Levin, Papantonio, & Rafferty — Doing Well by Doing Good 84. Glen Lerner, Lerner and Rowe – A Steady Hand in a Shifting Industry 101. Pratik Shah, EsquireTek — Discovering the Power of Automation 134. Darryl Isaacs, Isaacs & Isaacs — The Hammer: Insights from a Marketing Legend 104. Taly Goody, Goody Law Group — Finding PI Clients on TikTok 63. Joe Fried, Fried Goldberg LLC — How To Become An Expert And Revolutionize Your PI Niche 96. Brian Dean, Backlinko — Becoming a Linkable Source 83. Seth Godin — Differentiation: How to Make Your Law Firm a Purple Cow 73. Neil Patel, Neil Patel — Digital A New Approach to Content and Emerging Marketing Channels